Cargando…
EMP3 sustains oncogenic EGFR/CDK2 signaling by restricting receptor degradation in glioblastoma
Epithelial membrane protein 3 (EMP3) is an N-glycosylated tetraspanin with a putative trafficking function. It is highly expressed in isocitrate dehydrogenase-wild-type glioblastoma (IDH-wt GBM), and its high expression correlates with poor survival. However, the exact trafficking role of EMP3 and h...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10629159/ https://www.ncbi.nlm.nih.gov/pubmed/37936247 http://dx.doi.org/10.1186/s40478-023-01673-z |
_version_ | 1785131907074228224 |
---|---|
author | Martija, Antoni Andreu Krauß, Alexandra Bächle, Natalie Doth, Laura Christians, Arne Krunic, Damir Schneider, Martin Helm, Dominic Will, Rainer Hartmann, Christian Herold-Mende, Christel von Deimling, Andreas Pusch, Stefan |
author_facet | Martija, Antoni Andreu Krauß, Alexandra Bächle, Natalie Doth, Laura Christians, Arne Krunic, Damir Schneider, Martin Helm, Dominic Will, Rainer Hartmann, Christian Herold-Mende, Christel von Deimling, Andreas Pusch, Stefan |
author_sort | Martija, Antoni Andreu |
collection | PubMed |
description | Epithelial membrane protein 3 (EMP3) is an N-glycosylated tetraspanin with a putative trafficking function. It is highly expressed in isocitrate dehydrogenase-wild-type glioblastoma (IDH-wt GBM), and its high expression correlates with poor survival. However, the exact trafficking role of EMP3 and how it promotes oncogenic signaling in GBM remain unclear. Here, we show that EMP3 promotes EGFR/CDK2 signaling by regulating the trafficking and enhancing the stability of EGFR. BioID2-based proximity labeling revealed that EMP3 interacts with endocytic proteins involved in the vesicular transport of EGFR. EMP3 knockout (KO) enhances epidermal growth factor (EGF)-induced shuttling of EGFR into RAB7 + late endosomes, thereby promoting EGFR degradation. Increased EGFR degradation is rescued by the RAB7 negative regulator and novel EMP3 interactor TBC1D5. Phosphoproteomic and transcriptomic analyses further showed that EMP3 KO converges into the inhibition of the cyclin-dependent kinase CDK2 and the repression of EGFR-dependent and cell cycle transcriptional programs. Phenotypically, EMP3 KO cells exhibit reduced proliferation rates, blunted mitogenic response to EGF, and increased sensitivity to the pan-kinase inhibitor staurosporine and the EGFR inhibitor osimertinib. Furthermore, EGFR-dependent patient-derived glioblastoma stem cells display a transcriptomic signature consistent with reduced CDK2 activity, as well as increased susceptibility to CDK2 inhibition upon EMP3 knockdown. Lastly, using TCGA data, we showed that GBM tumors with high EMP3 expression have increased total and phosphorylated EGFR levels. Collectively, our findings demonstrate a novel EMP3-dependent mechanism by which EGFR/CDK2 activity is sustained in GBM. Consequently, EMP3’s stabilizing effect provides an additional layer of tumor cell resistance against targeted kinase inhibition. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40478-023-01673-z. |
format | Online Article Text |
id | pubmed-10629159 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-106291592023-11-08 EMP3 sustains oncogenic EGFR/CDK2 signaling by restricting receptor degradation in glioblastoma Martija, Antoni Andreu Krauß, Alexandra Bächle, Natalie Doth, Laura Christians, Arne Krunic, Damir Schneider, Martin Helm, Dominic Will, Rainer Hartmann, Christian Herold-Mende, Christel von Deimling, Andreas Pusch, Stefan Acta Neuropathol Commun Research Epithelial membrane protein 3 (EMP3) is an N-glycosylated tetraspanin with a putative trafficking function. It is highly expressed in isocitrate dehydrogenase-wild-type glioblastoma (IDH-wt GBM), and its high expression correlates with poor survival. However, the exact trafficking role of EMP3 and how it promotes oncogenic signaling in GBM remain unclear. Here, we show that EMP3 promotes EGFR/CDK2 signaling by regulating the trafficking and enhancing the stability of EGFR. BioID2-based proximity labeling revealed that EMP3 interacts with endocytic proteins involved in the vesicular transport of EGFR. EMP3 knockout (KO) enhances epidermal growth factor (EGF)-induced shuttling of EGFR into RAB7 + late endosomes, thereby promoting EGFR degradation. Increased EGFR degradation is rescued by the RAB7 negative regulator and novel EMP3 interactor TBC1D5. Phosphoproteomic and transcriptomic analyses further showed that EMP3 KO converges into the inhibition of the cyclin-dependent kinase CDK2 and the repression of EGFR-dependent and cell cycle transcriptional programs. Phenotypically, EMP3 KO cells exhibit reduced proliferation rates, blunted mitogenic response to EGF, and increased sensitivity to the pan-kinase inhibitor staurosporine and the EGFR inhibitor osimertinib. Furthermore, EGFR-dependent patient-derived glioblastoma stem cells display a transcriptomic signature consistent with reduced CDK2 activity, as well as increased susceptibility to CDK2 inhibition upon EMP3 knockdown. Lastly, using TCGA data, we showed that GBM tumors with high EMP3 expression have increased total and phosphorylated EGFR levels. Collectively, our findings demonstrate a novel EMP3-dependent mechanism by which EGFR/CDK2 activity is sustained in GBM. Consequently, EMP3’s stabilizing effect provides an additional layer of tumor cell resistance against targeted kinase inhibition. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40478-023-01673-z. BioMed Central 2023-11-07 /pmc/articles/PMC10629159/ /pubmed/37936247 http://dx.doi.org/10.1186/s40478-023-01673-z Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Martija, Antoni Andreu Krauß, Alexandra Bächle, Natalie Doth, Laura Christians, Arne Krunic, Damir Schneider, Martin Helm, Dominic Will, Rainer Hartmann, Christian Herold-Mende, Christel von Deimling, Andreas Pusch, Stefan EMP3 sustains oncogenic EGFR/CDK2 signaling by restricting receptor degradation in glioblastoma |
title | EMP3 sustains oncogenic EGFR/CDK2 signaling by restricting receptor degradation in glioblastoma |
title_full | EMP3 sustains oncogenic EGFR/CDK2 signaling by restricting receptor degradation in glioblastoma |
title_fullStr | EMP3 sustains oncogenic EGFR/CDK2 signaling by restricting receptor degradation in glioblastoma |
title_full_unstemmed | EMP3 sustains oncogenic EGFR/CDK2 signaling by restricting receptor degradation in glioblastoma |
title_short | EMP3 sustains oncogenic EGFR/CDK2 signaling by restricting receptor degradation in glioblastoma |
title_sort | emp3 sustains oncogenic egfr/cdk2 signaling by restricting receptor degradation in glioblastoma |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10629159/ https://www.ncbi.nlm.nih.gov/pubmed/37936247 http://dx.doi.org/10.1186/s40478-023-01673-z |
work_keys_str_mv | AT martijaantoniandreu emp3sustainsoncogenicegfrcdk2signalingbyrestrictingreceptordegradationinglioblastoma AT kraußalexandra emp3sustainsoncogenicegfrcdk2signalingbyrestrictingreceptordegradationinglioblastoma AT bachlenatalie emp3sustainsoncogenicegfrcdk2signalingbyrestrictingreceptordegradationinglioblastoma AT dothlaura emp3sustainsoncogenicegfrcdk2signalingbyrestrictingreceptordegradationinglioblastoma AT christiansarne emp3sustainsoncogenicegfrcdk2signalingbyrestrictingreceptordegradationinglioblastoma AT krunicdamir emp3sustainsoncogenicegfrcdk2signalingbyrestrictingreceptordegradationinglioblastoma AT schneidermartin emp3sustainsoncogenicegfrcdk2signalingbyrestrictingreceptordegradationinglioblastoma AT helmdominic emp3sustainsoncogenicegfrcdk2signalingbyrestrictingreceptordegradationinglioblastoma AT willrainer emp3sustainsoncogenicegfrcdk2signalingbyrestrictingreceptordegradationinglioblastoma AT hartmannchristian emp3sustainsoncogenicegfrcdk2signalingbyrestrictingreceptordegradationinglioblastoma AT heroldmendechristel emp3sustainsoncogenicegfrcdk2signalingbyrestrictingreceptordegradationinglioblastoma AT vondeimlingandreas emp3sustainsoncogenicegfrcdk2signalingbyrestrictingreceptordegradationinglioblastoma AT puschstefan emp3sustainsoncogenicegfrcdk2signalingbyrestrictingreceptordegradationinglioblastoma |